共 21 条
[1]
Thesafetyoflow molecularweightheparinsforthepreventionofthromboemboliceventsaftercardiover sionofatrialfibrillation. YigitZ,KucukogluMS,OkcunB ,etal. Japanese Heart Journal . 2003
[2]
Comparisonofximelagatranwithwarfarinforthepreventionofvenousthromboembolismaftertotalkneereplacement. FrancisCW,BerkowitzSD,CompPC ,etal. NEng1JMed . 2003
[3]
XimelagatranversuswarfarinforstrokepreventioninpatientswithnonvalvularatrialfibrillationSPORTIFⅡ:adoseguiding,tolerability,andsafetystudy. PetersenP,GrindM,AdlerJ,etal. Journal of the American College of Cardiology . 2003
[4]
Non valvularatrialfibrillationandstrokepreventionNationalbloodpressureadvisorycommitteeofthenationalheartfoundation. HankeyGJ. MedJAust . 2001
[5]
Europeanstrokepreventionstudy2Dipyridamoleandacetylsalicylicacidinthesecondarypreventionofstroke. DienerHC,CunhaL,ForbesC ,etal. JNeurolSci . 1996
[6]
Anticoagulant relatedbleedinginolderper sonswithatrialfibrillation:physicians’’fearsoftenunfounded. ManSonHingM,LaupacisA. Archives of Internal Medicine . 2003
[7]
Decidingonanticoagulatingtheoldestoldwithatrialfibrilla tion:insightsfromcost effectivenessanalysis. DesbiensNA. JAmGeriatrSoc . 2002
[8]
Optimalintensityofwarfarintherapyforsecondarypreventionofstrokeinpatientswithnonvalvularatrialfibrillation:amulticenter,prospective,randomizedtrialJapanesenonvalvularatrialfibrillation embolismsecondarypre ventioncooperativestudygroup. YamaguchiT. Stroke . 2000
[9]
Transoesophagealechocardiography guid edcardioversionofatrialfibrillationorflutterSelectionofalow riskgroupforimmediatecardioversion. RoijerA,EskilssonJ,OlssonB. European Heart Journal . 2000
[10]
EffectsofclopidogrelinadditiontoaspirininpatientswithacutecoronarysyndromeswithoutST segmenteleva tion. YusufS,ZhaoF,MehtaSR ,etal. The New England Journal of Medicine . 2001